Margarita Donica
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Impact of informative censoring on estimation and testing in randomized trials with delayed treatment effects.
Journal: Contemporary clinical trials
Published: August 12, 2024
Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.
Journal: Cancer medicine
Published: September 14, 2022
Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer.
Journal: Gynecologic oncology
Published: June 09, 2020
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 31, 2020
Prospective, Single-Arm, Longitudinal Study of Biomarkers in Real-World Patients with Severe Asthma.
Prospective, Single-Arm, Longitudinal Study of Biomarkers in Real-World Patients with Severe Asthma.
Journal: The journal of allergy and clinical immunology. In practice
Published: September 03, 2019
Outcome according to residual disease (surgeon's report vs pre-chemotherapy imaging) in patients with bevacizumab-treated ovarian cancer: Analysis of the ROSiA study.
Journal: Journal of surgical oncology
Published: March 07, 2019
Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 05, 2018
Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial.
Journal: JAMA oncology
Published: September 05, 2018
An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 22, 2018
Showing 1-9 of 9
Last Updated: 09/26/2026